ArticleAnnals of clinical and translational neurology2025
CSF Biomarker-Based Cognitive Trajectories in Parkinson's Disease-Subjective Cognitive Decline.
Article in Annals of clinical and translational neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Body Fluid-based Biomarkers for Cognitive Impairment in Parkinson's Disease.Annals of neurosciences · 2026Review
- Diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Parkinson's disease patients with subjective cognitive decline.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCognitive complaints without objective cognitive impairment in Parkinson's Disease, termed Parkinson's Disease-Subjective Cognitive Decline (PD-SCD), have been associated with cognitive decline. However, its progression is heterogeneous, highlighting the need for improved identification of patients at greater risk for deterioration. This cohort study aims to investigate associations between CSF biomarkers and cognitive decline in PD-SCD.
methodsWe included patients from the PPMI cohort with PD-SCD, available baseline CSF beta-amyloid
resultsA total of 80 patients were included, with a mean age of 62.1 years and a median disease duration of 5.6 months at baseline. Five patients were identified with biological AD, who showed a more pronounced decline in MoCA (year 7: β = -4.15, p = 0.009). After excluding AD patients, linear mixed-effects models (LMEM) demonstrated an association between baseline log-transformed Aβ
interpretationIn PD-SCD, baseline CSF Aβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.